{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T04:12:06Z","timestamp":1791000726451,"version":"4.1.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,5,22]],"date-time":"2020-05-22T00:00:00Z","timestamp":1590105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,5,22]],"date-time":"2020-05-22T00:00:00Z","timestamp":1590105600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100003820","name":"Hubei Provincial Population and Family Planning Commission","doi-asserted-by":"publisher","award":["2016-6"],"award-info":[{"award-number":["2016-6"]}],"id":[{"id":"10.13039\/501100003820","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1007\/s00280-020-04078-0","type":"journal-article","created":{"date-parts":[[2020,5,22]],"date-time":"2020-05-22T18:27:30Z","timestamp":1590172050000},"page":"1079-1087","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["MEK inhibition overcomes everolimus resistance in gastric cancer"],"prefix":"10.1007","volume":"85","author":[{"given":"Hongfang","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9991-7625","authenticated-orcid":false,"given":"Juan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,22]]},"reference":[{"issue":"1","key":"4078_CR1","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3322\/caac.21254","volume":"65","author":"RL Siegel","year":"2015","unstructured":"Siegel RL, Miller KD, Jemal A (2015) Cancer statistics. CA Cancer J Clin 65(1):5\u201329. https:\/\/doi.org\/10.3322\/caac.21254","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"4078_CR2","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1007\/s10434-999-0290-2","volume":"6","author":"W Polkowski","year":"1999","unstructured":"Polkowski W, van Sandick JW, Offerhaus GJ, ten Kate FJ, Mulder J, Obertop H, van Lanschot JJ (1999) Prognostic value of Lauren classification and c-erbB-2 oncogene overexpression in adenocarcinoma of the esophagus and gastroesophageal junction. Ann Surg Oncol 6(3):290\u2013297. https:\/\/doi.org\/10.1007\/s10434-999-0290-2","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"4078_CR3","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1097\/MOG.0000000000000395","volume":"33","author":"DH Ilson","year":"2017","unstructured":"Ilson DH (2017) Advances in the treatment of gastric cancer. Curr Opin Gastroenterol 33(6):473\u2013476. https:\/\/doi.org\/10.1097\/MOG.0000000000000395","journal-title":"Curr Opin Gastroenterol"},{"issue":"8","key":"4078_CR4","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.3748\/wjg.v22.i8.2403","volume":"22","author":"A Digklia","year":"2016","unstructured":"Digklia A, Wagner AD (2016) Advanced gastric cancer: current treatment landscape and future perspectives. World J Gastroenterol 22(8):2403\u20132414. https:\/\/doi.org\/10.3748\/wjg.v22.i8.2403","journal-title":"World J Gastroenterol"},{"issue":"11","key":"4078_CR5","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1016\/S1470-2045(14)70420-6","volume":"15","author":"H Wilke","year":"2014","unstructured":"Wilke H, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, Hironaka S, Sugimoto N, Lipatov O, Kim TY, Cunningham D, Rougier P, Komatsu Y, Ajani J, Emig M, Carlesi R, Ferry D, Chandrawansa K, Schwartz JD, Ohtsu A, Group RS (2014) Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol 15(11):1224\u20131235. https:\/\/doi.org\/10.1016\/S1470-2045(14)70420-6","journal-title":"Lancet Oncol"},{"issue":"1","key":"4078_CR6","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ccr.2007.05.008","volume":"12","author":"DA Guertin","year":"2007","unstructured":"Guertin DA, Sabatini DM (2007) Defining the role of mTOR in cancer. Cancer Cell 12(1):9\u201322. https:\/\/doi.org\/10.1016\/j.ccr.2007.05.008","journal-title":"Cancer Cell"},{"issue":"2","key":"4078_CR7","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.cell.2012.03.017","volume":"149","author":"M Laplante","year":"2012","unstructured":"Laplante M, Sabatini DM (2012) mTOR signaling in growth control and disease. Cell 149(2):274\u2013293. https:\/\/doi.org\/10.1016\/j.cell.2012.03.017","journal-title":"Cell"},{"issue":"10","key":"4078_CR8","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1042\/CS20150149","volume":"129","author":"U Saran","year":"2015","unstructured":"Saran U, Foti M, Dufour JF (2015) Cellular and molecular effects of the mTOR inhibitor everolimus. Clin Sci (Lond) 129(10):895\u2013914. https:\/\/doi.org\/10.1042\/CS20150149","journal-title":"Clin Sci (Lond)"},{"issue":"6","key":"4078_CR9","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1093\/jjco\/hyw194","volume":"47","author":"M Oyama","year":"2017","unstructured":"Oyama M, Sugiyama T, Nozawa M, Fujimoto K, Kishida T, Kimura G, Tokuda N, Hinotsu S, Shimozuma K, Akaza H, Ozono S (2017) Efficacy and safety of sequential use of everolimus in Japanese patients with advanced renal cell carcinoma after failure of first-line treatment with vascular endothelial growth factor receptor tyrosine kinase inhibitor: a multicenter phase II clinical trial. Jpn J Clin Oncol 47(6):551\u2013559. https:\/\/doi.org\/10.1093\/jjco\/hyw194","journal-title":"Jpn J Clin Oncol"},{"issue":"9637","key":"4078_CR10","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","volume":"372","author":"RJ Motzer","year":"2008","unstructured":"Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grunwald V, Thompson JA, Figlin RA, Hollaender N, Urbanowitz G, Berg WJ, Kay A, Lebwohl D, Ravaud A, Group R-S (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372(9637):449\u2013456. https:\/\/doi.org\/10.1016\/S0140-6736(08)61039-9","journal-title":"Lancet"},{"issue":"4","key":"4078_CR11","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1016\/j.ajpath.2013.07.005","volume":"183","author":"A Mohamed","year":"2013","unstructured":"Mohamed A, Krajewski K, Cakar B, Ma CX (2013) Targeted therapy for breast cancer. Am J Pathol 183(4):1096\u20131112. https:\/\/doi.org\/10.1016\/j.ajpath.2013.07.005","journal-title":"Am J Pathol"},{"issue":"31","key":"4078_CR12","doi-asserted-by":"publisher","first-page":"3935","DOI":"10.1200\/JCO.2012.48.3552","volume":"31","author":"A Ohtsu","year":"2013","unstructured":"Ohtsu A, Ajani JA, Bai YX, Bang YJ, Chung HC, Pan HM, Sahmoud T, Shen L, Yeh KH, Chin K, Muro K, Kim YH, Ferry D, Tebbutt NC, Al-Batran SE, Smith H, Costantini C, Rizvi S, Lebwohl D, Van Cutsem E (2013) Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study. J Clin Oncol 31(31):3935\u20133943. https:\/\/doi.org\/10.1200\/JCO.2012.48.3552","journal-title":"J Clin Oncol"},{"issue":"2","key":"4078_CR13","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1159\/000362671","volume":"87","author":"YC Shen","year":"2014","unstructured":"Shen YC, Li CP, Yen CJ, Hsu C, Lin YL, Lin ZZ, Chen LT, Su WC, Chao Y, Yeh KH, Cheng AL (2014) Phase II multicentered study of low-dose everolimus plus cisplatin and weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin as first-line treatment for patients with advanced gastric cancer. Oncology 87(2):104\u2013113. https:\/\/doi.org\/10.1159\/000362671","journal-title":"Oncology"},{"issue":"9","key":"4078_CR14","doi-asserted-by":"publisher","first-page":"e104413","DOI":"10.1371\/journal.pone.0104413","volume":"9","author":"ST Bailey","year":"2014","unstructured":"Bailey ST, Zhou B, Damrauer JS, Kris-hnan B, Wilson HL, Smith AM, Li M, Yeh JJ, Kim WY (2014) mTOR inhibition induces compensatory, therapeutically targetable MEK activation in renal cell carcinoma. PLoS ONE 9(9):e104413. https:\/\/doi.org\/10.1371\/journal.pone.0104413","journal-title":"PLoS ONE"},{"issue":"1","key":"4078_CR15","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s13045-019-0754-1","volume":"12","author":"H Hua","year":"2019","unstructured":"Hua H, Kong Q, Zhang H, Wang J, Luo T, Jiang Y (2019) Targeting mTOR for cancer therapy. J Hematol Oncol 12(1):71. https:\/\/doi.org\/10.1186\/s13045-019-0754-1","journal-title":"J Hematol Oncol"},{"issue":"34","key":"4078_CR16","doi-asserted-by":"publisher","first-page":"56698","DOI":"10.18632\/oncotarget.18082","volume":"8","author":"DE Butler","year":"2017","unstructured":"Butler DE, Marlein C, Walker HF, Frame FM, Mann VM, Simms MS, Davies BR, Collins AT, Maitland NJ (2017) Inhibition of the PI3K\/AKT\/mTOR pathway activates autophagy and compensatory Ras\/Raf\/MEK\/ERK signalling in prostate cancer. Oncotarget 8(34):56698\u201356713. https:\/\/doi.org\/10.18632\/oncotarget.18082","journal-title":"Oncotarget"},{"issue":"4","key":"4078_CR17","first-page":"1703","volume":"43","author":"SC Barranco","year":"1983","unstructured":"Barranco SC, Townsend CM Jr, Casartelli C, Macik BG, Burger NL, Boerwinkle WR, Gourley WK (1983) Establishment and characterization of an in vitro model system for human adenocarcinoma of the stomach. Cancer Res 43(4):1703\u20131709","journal-title":"Cancer Res"},{"issue":"6","key":"4078_CR18","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1007\/s40257-017-0292-y","volume":"18","author":"AM Grimaldi","year":"2017","unstructured":"Grimaldi AM, Simeone E, Festino L, Vanella V, Strudel M, Ascierto PA (2017) MEK inhibitors in the treatment of metastatic melanoma and solid tumors. Am J Clin Dermatol 18(6):745\u2013754. https:\/\/doi.org\/10.1007\/s40257-017-0292-y","journal-title":"Am J Clin Dermatol"},{"issue":"3","key":"4078_CR19","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1038\/cdd.2008.148","volume":"16","author":"K Balmanno","year":"2009","unstructured":"Balmanno K, Cook SJ (2009) Tumour cell survival signalling by the ERK1\/2 pathway. Cell Death Differ 16(3):368\u2013377. https:\/\/doi.org\/10.1038\/cdd.2008.148","journal-title":"Cell Death Differ"},{"issue":"5","key":"4078_CR20","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1158\/1078-0432.CCR-08-2138","volume":"15","author":"G Yu","year":"2009","unstructured":"Yu G, Wang J, Chen Y, Wang X, Pan J, Li G, Jia Z, Li Q, Yao JC, Xie K (2009) Overexpression of phosphorylated mammalian target of rapamycin predicts lymph node metastasis and prognosis of chinese patients with gastric cancer. Clin Cancer Res 15(5):1821\u20131829. https:\/\/doi.org\/10.1158\/1078-0432.CCR-08-2138","journal-title":"Clin Cancer Res"},{"key":"4078_CR21","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/1756-8722-2-45","volume":"2","author":"R Yuan","year":"2009","unstructured":"Yuan R, Kay A, Berg WJ, Lebwohl D (2009) Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy. J Hematol Oncol 2:45. https:\/\/doi.org\/10.1186\/1756-8722-2-45","journal-title":"J Hematol Oncol"},{"issue":"1","key":"4078_CR22","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s00280-011-1653-5","volume":"68","author":"T Lim","year":"2011","unstructured":"Lim T, Lee J, Lee DJ, Lee HY, Han B, Baek KK, Ahn HK, Lee SJ, Park SH, Park JO, Park YS, Lim HY, Kim KM, Kang WK (2011) Phase I trial of capecitabine plus everolimus (RAD001) in patients with previously treated metastatic gastric cancer. Cancer Chemother Pharmacol 68(1):255\u2013262. https:\/\/doi.org\/10.1007\/s00280-011-1653-5","journal-title":"Cancer Chemother Pharmacol"},{"issue":"11","key":"4078_CR23","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1200\/JCO.2009.26.2923","volume":"28","author":"T Doi","year":"2010","unstructured":"Doi T, Muro K, Boku N, Yamada Y, Nishina T, Takiuchi H, Komatsu Y, Hamamoto Y, Ohno N, Fujita Y, Robson M, Ohtsu A (2010) Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer. J Clin Oncol 28(11):1904\u20131910. https:\/\/doi.org\/10.1200\/JCO.2009.26.2923","journal-title":"J Clin Oncol"},{"issue":"6","key":"4078_CR24","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1007\/s10637-010-9464-9","volume":"29","author":"F Taguchi","year":"2011","unstructured":"Taguchi F, Kodera Y, Katanasaka Y, Yanagihara K, Tamura T, Koizumi F (2011) Efficacy of RAD001 (everolimus) against advanced gastric cancer with peritoneal dissemination. Invest New Drugs 29(6):1198\u20131205. https:\/\/doi.org\/10.1007\/s10637-010-9464-9","journal-title":"Invest New Drugs"},{"issue":"1","key":"4078_CR25","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s13046-019-1121-3","volume":"38","author":"H Fukamachi","year":"2019","unstructured":"Fukamachi H, Kim SK, Koh J, Lee HS, Sasaki Y, Yamashita K, Nishikawaji T, Shimada S, Akiyama Y, Byeon SJ, Bae DH, Okuno K, Nakagawa M, Tanioka T, Inokuchi M, Kawachi H, Tsuchiya K, Kojima K, Tokino T, Eishi Y, Kim YS, Kim WH, Yuasa Y, Tanaka S (2019) A subset of diffuse-type gastric cancer is susceptible to mTOR inhibitors and checkpoint inhibitors. J Exp Clin Cancer Res CR 38(1):127. https:\/\/doi.org\/10.1186\/s13046-019-1121-3","journal-title":"J Exp Clin Cancer Res CR"},{"key":"4078_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20102505","author":"IC Salaroglio","year":"2019","unstructured":"Salaroglio IC, Mungo E, Gazzano E, Kopecka J, Riganti C (2019) ERK is a pivotal player of chemo-immune-resistance in cancer. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms20102505","journal-title":"Int J Mol Sci"},{"key":"4078_CR27","doi-asserted-by":"publisher","first-page":"44123","DOI":"10.1038\/srep44123","volume":"7","author":"Y Chen","year":"2017","unstructured":"Chen Y, Liu YC, Sung YC, Ramjiawan RR, Lin TT, Chang CC, Jeng KS, Chang CF, Liu CH, Gao DY, Hsu FF, Duyverman AM, Kitahara S, Huang P, Dima S, Popescu I, Flaherty KT, Zhu AX, Bardeesy N, Jain RK, Benes CH, Duda DG (2017) Overcoming sorafenib evasion in hepatocellular carcinoma using CXCR4-targeted nanoparticles to co-deliver MEK-inhibitors. Sci Rep 7:44123. https:\/\/doi.org\/10.1038\/srep44123","journal-title":"Sci Rep"},{"key":"4078_CR28","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/978-3-319-91442-8_7","volume":"211","author":"R Zeiser","year":"2018","unstructured":"Zeiser R, Andrlova H, Meiss F (2018) Trametinib (GSK1120212). Recent Results Cancer Res 211:91\u2013100. https:\/\/doi.org\/10.1007\/978-3-319-91442-8_7","journal-title":"Recent Results Cancer Res"},{"issue":"3","key":"4078_CR29","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1007\/s10120-011-0102-9","volume":"15","author":"B Hotz","year":"2012","unstructured":"Hotz B, Keilholz U, Fusi A, Buhr HJ, Hotz HG (2012) In vitro and in vivo antitumor activity of cetuximab in human gastric cancer cell lines in relation to epidermal growth factor receptor (EGFR) expression and mutational phenotype. Gastric Cancer 15(3):252\u2013264. https:\/\/doi.org\/10.1007\/s10120-011-0102-9","journal-title":"Gastric Cancer"},{"issue":"2","key":"4078_CR30","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1002\/jso.23357","volume":"108","author":"TN Tran","year":"2013","unstructured":"Tran TN, Brettingham-Moore K, Duong CP, Mitchell C, Clemons NJ, Phillips WA (2013) Molecular changes in the phosphatidylinositide 3-kinase (PI3K) pathway are common in gastric cancer. J Surg Oncol 108(2):113\u2013120. https:\/\/doi.org\/10.1002\/jso.23357","journal-title":"J Surg Oncol"},{"issue":"3","key":"4078_CR31","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.ccr.2005.02.008","volume":"7","author":"TT Tan","year":"2005","unstructured":"Tan TT, Degenhardt K, Nelson DA, Beaudoin B, Nieves-Neira W, Bouillet P, Villunger A, Adams JM, White E (2005) Key roles of BIM-driven apoptosis in epithelial tumors and rational chemotherapy. Cancer Cell 7(3):227\u2013238. https:\/\/doi.org\/10.1016\/j.ccr.2005.02.008","journal-title":"Cancer Cell"},{"issue":"25","key":"4078_CR32","doi-asserted-by":"publisher","first-page":"22384","DOI":"10.1074\/jbc.M111.239566","volume":"286","author":"J Wang","year":"2011","unstructured":"Wang J, Zhou JY, Wu GS (2011) Bim protein degradation contributes to cisplatin resistance. J Biol Chem 286(25):22384\u201322392. https:\/\/doi.org\/10.1074\/jbc.M111.239566","journal-title":"J Biol Chem"},{"issue":"12","key":"4078_CR33","doi-asserted-by":"publisher","first-page":"9339","DOI":"10.1007\/s13277-015-3671-0","volume":"36","author":"I Dogan Turacli","year":"2015","unstructured":"Dogan Turacli I, Ozkan AC, Ekmekci A (2015) The comparison between dual inhibition of mTOR with MAPK and PI3K signaling pathways in KRAS mutant NSCLC cell lines. Tumour Biol 36(12):9339\u20139345. https:\/\/doi.org\/10.1007\/s13277-015-3671-0","journal-title":"Tumour Biol"},{"issue":"6","key":"4078_CR34","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1007\/s10637-014-0149-7","volume":"32","author":"F Ewald","year":"2014","unstructured":"Ewald F, Norz D, Grottke A, Hofmann BT, Nashan B, Jucker M (2014) Dual Inhibition of PI3K-AKT-mTOR- and RAF-MEK-ERK-signaling is synergistic in cholangiocarcinoma and reverses acquired resistance to MEK-inhibitors. Invest New Drugs 32(6):1144\u20131154. https:\/\/doi.org\/10.1007\/s10637-014-0149-7","journal-title":"Invest New Drugs"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-020-04078-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-020-04078-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-020-04078-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,21]],"date-time":"2021-05-21T23:20:48Z","timestamp":1621639248000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-020-04078-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,22]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["4078"],"URL":"https:\/\/doi.org\/10.1007\/s00280-020-04078-0","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,22]]},"assertion":[{"value":"7 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures involving animals were conducted according to the guidelines approved by the Institutional Animal Care and Use Committee of Hubei University of Arts and Science.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human participants and\/or animals"}}]}}